Mar. 29 at 3:08 PM
$CORT The list from CORT is going:
- Korlym (Mifeprostone) for Cushing Syndrome,
- Lifyorli (Relacorilant) for PROC,
- Relacorilant for Cushing Syndrome,
- Dazucorilant for ALS,
- Miricorilant for NASH,
- Nenocorilant for solid tumors.
The "Corilant" class of compounds will follow the other 2 blockbuster classes of compounds, "Gliflozin" (SGLT inhibitors) and "Glutide/Patide (GLP-1 agonists), to become a super star in the pharmaceutical world.
What most amazing is the fact that the clinical development of all these "Corilant" class of drugs are self-funded by CORT using profits from Korlym with very bumpy and turbulent history - full of unwanted attentions from 1) oversized shorting of its stock; 2) generics legal challenges; 3) class-action vultures; and unfriendly press sponsored by shorties.
I am happy to report that CORT's days under the sun has finally arrived. It's revenue will soon hit 1B$/yr mark, then 2B$, 3B$ ..., its SP will either hit
$100,
$200 ..., or be bought out.
